At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 104 enrolled
Drug / intervention
Liposomal Bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty: A Single Blinded Prospective Randomized Control Trial
In Brief
A Phase 4 clinical trial evaluating Liposomal Bupivacaine and Bupivacaine Hydrochloride for Arthropathy Shoulder. Completed, enrolled 104 participants across 1 site.
Detailed Summary
The objective of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with standard bupivacaine alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthropathy Shoulder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedSep 10, 2018
Enrollment StartOct 29, 2018
Primary CompletionFeb 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.8 years ago
Interventions
Liposomal Bupivacainedrug
Interscalene Nerve Blocks
Bupivacaine Hydrochloridedrug
Interscalene Nerve Blocks